Abstract: A method for regenerating different types of copper-containing aluminum alloys using aluminum alloy scrap from aeronautical industry includes detecting a chemical composition of said aluminum alloy scrap and optionally adding a suitable amount of a metal or alloy additive according to a composition requirement of a target aluminum-copper alloy, thereby obtaining a mixture of aluminum alloy scrap and metal or alloy additive; vacuum smelting the mixture of aluminum alloy scrap and metal or alloy additive in a vacuum furnace, wherein impurities are removed and an aluminum alloy solution is formed; filtering the aluminum alloy solution using a filter to obtain a melt comprising a target aluminum alloy composition; and casting the target aluminum alloy composition from said melt.

Abstract: A method for recycling an aluminum alloy scrap includes performing selective oxidation roasting and washing treatment on the aluminum alloy scrap to obtain an uncoated aluminum alloy scrap; melting the uncoated aluminum alloy scrap in a refining furnace to obtain aluminum alloy melt liquid, online-detecting components of the aluminum alloy melt liquid and adding a metallic copper, a copper alloy, a magnesium alloy or a zinc alloy to the aluminum alloy melt liquid according to the requirements of target alloy components, performing pressure-controlled and oxygen-controlled melting through regulating pressure intensity and oxygen partial pressure in the refining furnace and coupling an external-field stirring mode to obtain refining aluminum alloy melt liquid; filtering the refining aluminum alloy melt liquid, to obtain an aluminum alloy melt with the target alloy components; and casting the aluminum alloy melt.

Abstract: The present disclosure relates to use of Rivastigmine in the preparation of an anti-radiation medicament, and belongs to the field of medical technology. The present disclosure provides use of Rivastigmine in the preparation of an anti-radiation medicament. Researches show that Rivastigmine significantly promoted the proliferation of Lgr5+ stem cells receiving 10 Gy radiation (after being irradiated with 10 Gy radiation for 10 d, Lgr5+ stem cells cultured in a Rivastigmine-containing culture solution had an increment 14.2 times of that of the Lgr5+ stem cells cultured in a Rivastigmine-free culture solution). Rivastigmine also significantly reduced the mortality of mice after being irradiated with 10 Gy radiation (after receiving 10 Gy whole body irradiation, all the mice not intraperitoneally injected Rivastigmine died within 10 d; and for the mice intraperitoneally injected Rivastigmine, the survival rate of the mice was still greater than 40% 30 d later), and thus might have good radiation-proof effect.

Abstract: The present disclosure relates to use of Rivastigmine in the preparation of an anti-radiation medicament, and belongs to the field of medical technology. The present disclosure provides use of Rivastigmine in the preparation of an anti-radiation medicament. Researches show that Rivastigmine significantly promoted the proliferation of Lgr5+ stem cells receiving 10Gy radiation (after being irradiated with 10Gy radiation for 10 d, Lgr5+ stem cells cultured in a Rivastigmine-containing culture solution had an increment 14.2 times of that of the Lgr5+ stem cells cultured in a Rivastigmine-free culture solution). Rivastigmine also significantly reduced the mortality of mice after being irradiated with 10Gy radiation (after receiving 10Gy whole body irradiation, all the mice not intraperitoneally injected Rivastigmine died within 10 d; and for the mice intraperitoneally injected Rivastigmine, the survival rate of the mice was still greater than 40% 30 d later), and thus might have good radiation-proof effect.

Abstract: Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.

Abstract: Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.

Abstract: Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.

Abstract: The present invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section and a preparation method and purpose thereof. The fusion protein has the biological activity of GLP-1, and also has a significantly prolonged half-life in vivo. The fusion protein can be used to treat type II diabetes, obesity, and other diseases that are treated by decreasing serum glucose, suppressing gastrointestinal motility, and emptying or suppressing food intake.

Abstract: Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine.

Abstract: The present invention provides an anthropogenic glucagon-like peptide-1 (GLP-1) recombinant protein molecule fused with an anthropogenic immunoglobulin subtype (IgG2) Fc section and a preparation method and purpose thereof. The fusion protein has the biological activity of GLP-1, and also has a significantly prolonged half-life in vivo. The fusion protein can be used to treat type II diabetes, obesity, and other diseases that are treated by decreasing serum glucose, suppressing gastrointestinal motility, and emptying or suppressing food intake.

Abstract: The present application is directed to compounds of Formula I: wherein R1-R9, X, Y and Z are as defined in the application, and to the use of the compounds of Formula I, for example, for the fluorescent labeling of oligonucleotides.

Abstract: The present application is directed to compounds of Formula I: wherein R1-R9, X, Y and Z are as defined in the application, and to the use of the compounds of Formula I, for example, for the fluorescent labeling of oligonucleotides.